dal-GenE (Completed)
A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS). The Dal-GenE trial
- Medicine
- dalcetrapib
- Population
- ASCVD
- Phase
- III
- Starting year
- 2015
- More information
- ClinicalTrials.gov